Evicenter
P&T meetings

Cytisinicline

Smoking cessation

Last updated
86 sources

Clinical evidence

Single-dose pharmacokinetic study

7 evidence topics · 2 sources

Objective
Pharmacokinetic objective

“pharmacokinetics of cytisine” (opens the source at this quote in a new tab)

Location and study date

No evidence found.

Study design
Exposure design

“Single-dose pharmacokinetics” (opens the source at this quote in a new tab)

Eligibility criteria
Population

“healthy smokers” (opens the source at this quote in a new tab)

Treatment
Oral dose

“3 mg” (opens the source at this quote in a new tab)

Study outcomes
Rationale for using plasma and urinary cytisine concentrations as the pharmacokinetic endpoints

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Pharmacokinetic elimination findings

“Cytisine was renally excreted and detected as an unchanged drug. No metabolites were detected in plasma or urine collected in the study.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse reactions

“No adverse reactions were reported.” (opens the source at this quote in a new tab)

Study limitations
Summary

The study characterized a single dose in healthy smokers. It does not establish smoking-cessation efficacy or the safety of repeated administration for 6 or 12 weeks.